DOCSLIB.ORG

Updated Criteria for Diagnosing Multiple Sclerosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Updated Criteria for Diagnosing Multiple Sclerosis r e v i e w a r t i c l e Updated criteria for diagnosing Multiple Sclerosis or in the case of progressive MS, a slow or step- Key take home messages wise progression of disability over a period of • The diagnostic criteria for MS have at least six months been recently updated • and objective clinical evidence of lesions in • These criteria should only be applied two or more distinct sites in the white matter to populations in whom MS is of the central nervous system common and patients who present • with no more satisfactory explanation. Peter Brex with typical symptoms for which no The Schumacher criteria were purely clinical, MB BS, MD, FRCP is a Consultant Neurologist at King’s College Hospital better explanation can be found although investigations were encouraged (blood, NHS Foundation Trust. He trained in • All patients with suspected MS should urine, chest X-ray, CSF analysis) to exclude London and was appointed to his current have an MRI brain scan; spinal cord alternative conditions. role in 2005. He specialises in multiple imaging is not mandatory Over the next few years modifications to the sclerosis, with a particular interest in early 2,3 prognostic markers and the management • Unmatched oligoclonal bands in the Schumacher criteria were published but in 1983 of MS during pregnancy. CSF can be used as a substitute for the Schumacher criteria were replaced by criteria demonstrating dissemination in time, developed by a committee chaired by Charles allowing an earlier diagnosis than was Poser (1923 – 2010).4 The Poser criteria incorpor- previously possible ated laboratory and clinical tests developed in the previous decade to support the diagnosis with ‘paraclinical evidence’ of lesions. This included Abstract evoked potentials, computed tomography (CT) The fourth update of the McDonald criteria or NMR scans (as MRI was known in its early enables an earlier diagnosis of MS in people days), as well as induced hyperthermia (the hot presenting with typical symptoms. It broadens bath test) and expert urological assessment. The Victoria Williams MRI evidence for dissemination in space to acceptable age of onset was extended to 10 to has been a Consultant Neurologist since include symptomatic and cortical lesions and 59 years of age. The criteria emphasised that 2009. She is an MS specialist at Guy's and allows dissemination in time to be demonstrated symptoms should be consistent with MS and the St Thomas' and King's College Hospitals by unmatched oligoclonal bands in the CSF diagnosis made by a ‘competent neurologist’. NHS Trusts. as well as by new or enhancing MRI lesions. The criteria divided patients into two groups Correspondence to: To avoid misdiagnosis, it should be used with – ‘Definite’ and ‘Probable’ MS – each with PA Brex, caution in patients with atypical symptoms or in two sub-groups – ‘Clinical’ and ‘Laboratory- Department of Neurology, populations in which MS is uncommon. supported’; the latter referring to the presence King’s College Hospital NHS Trust, Denmark Hill, of oligoclonal bands or raised IgG in the CSF. London The history of diagnostic criteria for Clinically Definite MS became the requirement SE5 9RS. multiple sclerosis (MS) for entry into therapeutic trials of the time and Conflict of interest statement: Dr Brex Multiple Sclerosis (MS) became widely required two attacks and objective clinical and Dr Williams have between them recognised after Jean-Martin Charcot (1825 – evidence of two lesions; or two attacks with received honoraria from Biogen, MedDay 1893) (Figure 1a) described it in his lectures in objective evidence of one lesion and paraclinical pharmacuticals, Merck, Roche, Sanofi- Genzyme & Teva. the late 18th century. Prior to this patients with MS evidence of another separate lesion. Certain would typically have been described as having historical symptoms could be substituted for clin- Provenance and peer review: Submitted a palsy, paralysis or paraplegia, without much ical evidence in some instances, e.g. Lhermitte’s and externally reviewed. understanding as to the cause. phenomenon in the absence of cervical spondyl- Date submitted: 1/4/18 In May 1960, a symposium on the ‘Evaluation osis; painful optic neuritis in an under 50-year-old, Date submitted after peer review: 4/10/18 of Drug Therapy in Neurologic and Sensory trigeminal neuralgia in an under 40-year-old. Acceptance date: 11/10/18 Diseases’ held at the University of Wisconsin In 2001, Poser’s criteria were replaced by To cite: Brex P, Williams V. concluded that criteria for MS were required McDonald’s criteria,5 developed by the ACNR 2018;18(2):14-16. to provide a common ground of terminology International Panel on MS Diagnostics, chaired amongst investigators to facilitate therapeutic at their first meeting by Ian McDonald (1933 – trials. 2006) (Figure 1b). These criteria placed a much A committee of experts chaired by George greater emphasis on the use of MRI lesions (areas Schumacher (1912 – 2008) was formed and of T2 hyperintensity at least 3mm in cross-sec- published the Schumacher criteria in 1965.1 This tion) to demonstrate dissemination of disease enabled a diagnosis of definite MS in in space and time. These criteria enabled a • a typically aged individual (defined as diagnosis of MS after a single clinical attack between 10 and 50 years) which allowed clinical trials to include patients • with a compatible history – attacks lasting at at a much earlier stage than had previously been least 24 hours, separated by at least a month; possible. Progressive MS, which had not been 14 > ACNR > VOLUME 18 NUMBER 2 > NOVEMBER-JANUARY 2019 r e v i e w a r t i c l e regions. Changes to the diagnostic criteria were evidence-based and not just based on expert opinion. The most significant change is the revital- isation of the role of CSF analysis. The finding or tfo or more oligoclonal bands was found to be more reliable than a raised IgG index and their presence has been shown to have high predictive value for conversion from clinically isolated syndromes to MS. The panel agreed the presence of unmatched oligoclonal bands in the CSF could confirm dissemination in time in place of clinical or MRI evidence. The Figure 1b: panel also stressed the importance of CSF in Ian McDonald (1933 – 2006) excluding MS mimics. Image courtesy The MRI criteria for dissemination in space of Queen Square have also been changed. Cortical lesions can Figure 1a: Jean-Martin Charcot (1825 – 1893). Archive. now be counted in place of juxtacortical ones when assessing for lesions in one of the four typical sites (the others sites are periv- Table 1. New diagnostic criteria for RR MS8 entricular, brainstem or spinal cord lesion). Number Number of lesions Additional evidence required However, cortical lesions are not well appreci- of clinical with objective ated on currently available clinical MRI scans attacks* clinical evidence conducted outside of research and so this will ≥ 2 ≥ 2 None not have a great impact on most clinicians. The panel did not increase the number of ≥ 2 1 plus good historical None evidence periventricular lesions required, as was recom- mended in a 2016 MAGNIMS MRI criteria ≥ 2 1 Dissemination in space by a further clinical episode at paper,9 but suggested this may be advisable in another site or by MRI older patients and those at high risk of having 1 ≥ 2 Dissemination in time by a further clinical episode, by MRI white matter lesions, e.g. vascular risk factors, or the presence of CSF oligoclonal bands migraine. They did allow for the inclusion of 1 1 Dissemination in space by a further clinical episode at symptomatic lesions when assessing for radio- another site or by MRI logical evidence of dissemination in space – an exception being high signal in the optic AND nerves in people with optic neuritis. Dissemination in time by a further clinical episode, by MRI As with the criteria that have predated it, the or the presence of CSF oligoclonal bands McDonald criteria do enable MS to be diagnosed without the need for any supporting investiga- *attacks should be separated by at least 30 days between onset tions, but the panel recommended all patients in whom a diagnosis of MS was being considered simplify the criteria.6,7 The number of lesions should have an MRI brain. An MRI of the cord is 8 Table 2. New diagnostic criteria for PP MS required to provide evidence of dissemination not mandatory but advisable when signs localise 1 year of disability progression (retrospectively in space have been reduced and evidence to the cord, in progressive MS and in populations or prospectively determined) independent of of dissemination of disease in time may be in whom MS is more unusual. clinical relapse. obtained from a single MRI with both enhan- Whilst the sensitivity and specificity of the cing and non-enhancing lesions. The criteria McDonald MRI criteria have been shown to be Plus two of the following criteria: for progressive MS were changed so that high when applied to patients with typically • One or more T2-hyperintense lesions insidious neurological progression became clinically isolated syndromes suggestive of characteristic of multiple sclerosis in one the main requirement and oligoclonal bands MS,10 there have been a number of papers or more of the following brain regions: or elevated IgG index in the CSF were no published demonstrating that they over-diag- periventricular, cortical or juxtacortical, or longer mandatory if there were typical MRI nose MS in a ‘real world’ setting.11-13 The infratentorial findings in the brain and spinal cord. The term McDonald criteria were not developed to • Two or more T2-hyperintense lesions in ‘possible MS’ was added for people with a diagnose MS in patients with atypical symp- the spinal cord typical clinically isolated syndrome who did toms or to distinguish it from other conditions not meet the criteria.
Load more

Recommended publications
  • Headache in Multiple Sclerosis from a Different Perspective: a Prospective Study
    Volume 9 • Number 1 • March 2018 JOURNAL OF CLINICAL AND RESEARCHORIGINAL ARTICLEARTICLE EXPERIMENTAL INVESTIGATIONS Headache in Multiple Sclerosis from A Different Perspective: A Prospective Study Gökhan Özer¹, Ufuk Ergün², Levent Ertuğrul İnan³ 1 Sanko University Faculty of Medicine, Department of Neurology, Gaziantep, ABSTRACT Turkey Objective: It is known that patients with multiple sclerosis have a high incidence of headache. 2 Kırıkkale University School of Medicine, Kırıkkale, Turkey Although there is increasing evidence to suggest that periaqueductal gray matter (PAG) plays 3 Bozok University School of Medicine, a role in the pathophysiology of migraine headache, it is not known whether the type of Yozgat, Turkey headache may be a predictor of a MS relapse. Patients and Methods: The study enrolled 100 patients (68 females, 32 males) with clinically confirmed MS diagnosis established by McDonald diagnostic criteria. The type and duration of MS, MRI localization of lesions and cognitive status were recorded for all patients. Patients were questioned whether they experience headache during MS attacks. Results: Sixty-eight percent of the patients had headache and 32% of the patients were free of headache. Of the patients with headache, 16% had tension –type headache (TTH), 14% had migraine, 11% had primary stabbing headache (PSH), 8% had TTH+ migraine, 6% had PSH+ migraine, 6% had medication overuse headache , 2% had medication overuse headache + E-mail: [email protected] migraine, 2% had paroxysmal hemicrania, 1% had cervicogenic headache, 1% had chronic TTH, E-mail: [email protected] and 1% had unclassified headache. There was a statistically significant relationship between the E-mail: [email protected] presence of headache and MS relapse (p<0.001).
    [Show full text]
  • ANKRD55 and DHCR7 Are Novel Multiple Sclerosis Risk Loci
    Genes and Immunity (2012) 13, 253 --257 & 2012 Macmillan Publishers Limited All rights reserved 1466-4879/12 www.nature.com/gene ORIGINAL ARTICLE ANKRD55 and DHCR7 are novel multiple sclerosis risk loci I Alloza1,14, D Otaegui2,14, A Lopez de Lapuente1, A Antigu¨ edad3, J Varade´ 4,CNu´n˜ez4, R Arroyo5, E Urcelay4, O Fernandez6, L Leyva6, M Fedetz7, G Izquierdo8, M Lucas9, B Oliver-Martos6, A Alcina7, A Saiz10, Y Blanco10, M Comabella11, X Montalban11, J Olascoaga12, F Matesanz7,8,14 and K Vandenbroeck1,13,14 Multiple sclerosis (MS) shares some risk genes with other disorders hallmarked by an autoimmune pathogenesis, most notably IL2RA and CLEC16A. We analyzed 10 single-nucleotide polymorphisms (SNPs) in nine risk genes, which recently emerged from a series of non-MS genome-wide association studies (GWAS), in a Spanish cohort comprising 2895 MS patients and 2942 controls. We identified two SNPs associated with MS. The first SNP, rs6859219, located in ANKRD55 (Chr5), was recently discovered in a meta-analysis of GWAS on rheumatoid arthritis (RA), and emerged from this study with genome-wide significance (odds ratio (OR) ¼ 1.35; P ¼ 2.3 Â 10À9). The second SNP, rs12785878, is located near DHCR7 (Chr11), a genetic determinant of vitamin D insufficiency, and showed a size effect in MS similar to that recently observed in Type 1 diabetes (T1D; OR ¼ 1.10; P ¼ 0.009). ANKRD55 is a gene of unknown function, and is flanked proximally by the IL6ST-- IL31RA gene cluster. However, rs6859219 did not show correlation with a series of haplotype-tagging SNPs covering IL6ST--IL31RA, analyzed in a subset of our dataset (D0o 0.31; r2o 0.011).
    [Show full text]
  • Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort Kallweit, U ; Jelcic, I ; Braun, N ; Fischer, H ; Zörner, B ; Schreiner, B ; Sokolov, A A ; Martin, R ; Weller, M ; Linnebank, M Abstract: OBJECTIVES: Therapy for relapsing-remitting multiple sclerosis with natalizumab (Tysabri; Biogen Idec) has been shown to be effective in the reduction of the clinical relapse rate and disability progression. However, real-life longitudinal data, including years before baseline, are rare. METHODS: An observational single-center study was carried out. We analyzed data from 64 consecutive patients with multiple sclerosis. RESULTS: After 1 year of treatment (n = 64), score on the Expanded Disability Status Scale (EDSS) decreased by 0.47 points (P = 0.047) and the annualized relapse rate (ARR) decreased by 82% (P < 0.001). After 2 years (n = 41), EDSS score was still reduced by 0.28 (not significant) and ARR was reduced by 69% (P < 0.001). After 3 years (n = 23), EDSS score was reduced by 0.26 (not significant), and ARR was reduced by 77% (P < 0.001). Reduction of EDSS score andARRdid not depend on baseline ARR (1-2 vs >2) or EDSS score and was not biased by exceptional high disease activity or relapses around baseline. CONCLUSIONS: These real-life data reinforce that natalizumab is effective over years, reduces ARR, and stabilizes EDSS score independent of baseline ARR, baseline EDSS score, or baseline treatment.
    [Show full text]
  • Research Article Increasing Incidence in Relapsing-Remitting MS and High Rates Among Young Women in Finland: a Thirty-Year Follow-Up
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Multiple Sclerosis International Volume 2014, Article ID 186950, 8 pages http://dx.doi.org/10.1155/2014/186950 Research Article Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up Marja-Liisa Sumelahti,1,2 Markus H. A. Holmberg,1 Annukka Murtonen,1 Heini Huhtala,3 and Irina Elovaara1,2 1 School of Medicine, University of Tampere, Arvo 312, 33014 Tampere, Finland 2 Tampere University Hospital, P.O. Box 2000, 33521 Tampere, Finland 3 School of Health Sciences, University of Tampere, 33014 Tampere, Finland Correspondence should be addressed to Marja-Liisa Sumelahti; [email protected] Received 28 May 2014; Revised 23 September 2014; Accepted 9 October 2014; Published 9 November 2014 Academic Editor: Bianca Weinstock-Guttman Copyright © 2014 Marja-Liisa Sumelahti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Object. Gender and disease course specific incidences were studied in high- and medium-risk regions of MS in Finland. Methods. Age- and gender-specific incidences with 95% CIs were calculated in 10-year periods from 1981 to 2010. Poser diagnostic criteria were used and compared with the McDonald criteria from 2001 to 2010. Association between age and diagnostic delay over time was assessed by using the Kruskal-Wallis test. Results. 1419 (89%) RRMS and 198 (11%) PPMS cases were included.
    [Show full text]
  • Efficacy and Safety of Mitoxantrone, As an Initial Therapy, in Multiple Sclerosis: Experience in an Indian Tertiary Care Setting
    Original Article Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting B. S. Singhal, Sheth Geeta, Shilpa G. Hundalani, Suresh Menon Department of Neurology, Bombay Hospital Institute of Medical Sciences, India Abstract Background and Purpose: Mitoxantrone is an approved disease modifying agent for treatment of multiple sclerosis (MS). The aim of the study was to assess its efficacy and safety in Indian MS patients. Materials and Methods: A total of 23 patients with clinically definite MS (Poser criteria) were enrolled in an open label study. Of which, 21 satisfied the McDonald’s criteria for MS and two satisfied the diagnostic criteria of neuromyelitis optica (NMO). The numbers of relapses and expanded disability status scale (EDSS) score were used as primary and secondary outcome measures. The patients were monitored for the adverse effects. Results: In 17 (15 MS and two NMO) patients who completed one year of therapy, there was significant difference in the mean annual relapse rates [before 0.879 6 0.58; on mitoxantrone 0.091 6 0.17, (P 5 0.003)]. Of the 17 patients, ten (MS 9 and NMO 1) completed therapy for two years. Annual relapse rates [before (1.024 6 0.59), on therapy (0.155 6 0.21), (P 5 0.0054)] and EDSS score [before start of therapy 5.3, at the end of therapy 2.4, (P 5 0.001)] showed significant benefit in the ten patients who completed Address for correspondence: Dr. B. S. Singhal, two years therapy. This benefit persisted during the mean follow-up period of two and a Bombay Hospital Institute of half years after completion of therapy.
    [Show full text]
  • Fingolimod (Gilenya)
    Clinical Policy: Fingolimod (Gilenya) Reference Number: HIM.PA.SP10 Effective Date: 05/17 Coding Implications Last Review Date: Revision Log Line of Business: Health Insurance Marketplace See Important Reminder at the end of this policy for important regulatory and legal information. Description Fingolimod (Gilenya®) is a sphingosine 1-phosphate receptor modulator. FDA approved indication Gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. Policy/Criteria Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria I. Initial Approval Criteria A. Multiple Sclerosis (must meet all): 1. Diagnosis of relapsing MS established by magnetic resonance imaging (MRI); 2. Prescribed by or in consultation with a neurologist; 3. Member will not use other disease modifying therapies for MS concurrently; 4. Dose does not exceed 0.5 mg per day (1 capsule per day). Approval duration: 6 months B. Other diagnoses/indications 1. Refer to HIM.PHAR.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). II. Continued Therapy A. Multiple Sclerosis (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2. Documentation of positive response to therapy (e.g., improved or maintained disease control evidenced by increase in Expanded Disability Status Scale (EDSS) or reduction in relapses or MRI lesions); 3. Member is not using other disease modifying therapies for MS concurrently; 4. If request is for a dose increase, new dose does not exceed 0.5 mg per day (1 capsule per day).
    [Show full text]
  • Oral MS Disease-Modifying Therapies C21142-A
    Drug and Biologic Coverage Criteria Effective Date: 05/01/2019 Last P&T Approval/Version: 07/28/2021 Next Review Due By: 08/2022 Policy Number: C21142-A Oral MS Disease-Modifying Therapies PRODUCTS AFFECTED Mayzent (siponimod), Aubagio (teriflunomide), Gilenya (fingolimod), Mavenclad (cladribine), Tecfidera (dimethyl fumarate), Vumerity (diroximel fumarate), Bafiertam (monomethyl fumarate),dimethyl fumarate, Zeposia (ozanimod), Ponvory (ponesimod) COVERAGE POLICY Coverage for services, procedures, medical devices, and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines Documentation Requirements: Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A.
    [Show full text]
  • Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value
    Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Draft Evidence Report November 22, 2016 Prepared for ©Institute for Clinical and Economic Review, 2016 ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group Jeffrey A. Tice, MD Marita Zimmermann, MPH, PhD Associate Professor of Medicine Research Fellow University of California, San Francisco Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy Rick Chapman, PhD, MS University of Washington Director of Health Economics Institute for Clinical and Economic Review Elizabeth Brouwer, MPH Graduate Student Varun Kumar, MBBS, MPH, MSc Pharmaceutical Outcomes Research and Policy Health Economist Program, Department of Pharmacy Institute for Clinical and Economic Review University of Washington Anne M. Loos, MA Josh J. Carlson, PhD, MPH Senior Research Associate Associate Professor Institute for Clinical and Economic Review Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy Shanshan Liu, MS, MPH University of Washington Research Associate Institute for Clinical and Economic Review Matt Seidner, BS Program Manager The role of the University of Washington (UW) School of Institute for Clinical and Economic Review Pharmacy Modeling Group is limited to the development of the cost-effectiveness model, and the resulting ICER reports do not necessarily represent the views of the UW. Daniel A. Ollendorf, PhD Chief Scientific Officer Institute for Clinical and Economic Review David Rind, MD Chief Medical Officer Institute for Clinical and Economic Review Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review DATE OF PUBLICATION: November 22, 2016 We would also like to thank Margaret Webb for her contributions to this report.
    [Show full text]
  • Multiple Sclerosis Accepted: 15 May 2016 Receiving Tysabri
    Iranian Journal Letter to Editor of Neurology Iran J Neurol 2016; 15(3): 175-176 Bacterial meningitis in a patient Received: 10 Mar 2016 with multiple sclerosis Accepted: 15 May 2016 receiving Tysabri Abdorreza Naser Moghadasi1, Soroor Advani2, Shiva Rahimi2 1 Multiple Sclerosis Research Center, Neuroscience Institute, Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran 2 Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran Keywords lesions (Figure 1-A) with no evidence of PML or Bacterial Meningitis; Multiple Sclerosis; Tysabri HSE encephalitis. Meningeal enhancement was seen after the injection of the contrast medium (Figure 1-B). The most important adverse effect of natalizumab is progressive multifocal leukoencephalopathy (PML).1 Apart from PML, there are reports of other cerebral infections including herpes simplex encephalitis (HSE)2,3 and cryptococcal meningitis4 in the literature. The patient was a 29-year-old woman, a known case of multiple sclerosis (MS) for at least 5 years. She was treated using natalizumab since 6 month before. She was under treatment with prednisolone 1 g daily for 5 days for optic neuritis, which was 2 weeks before the onset of symptoms of meningitis. Approximately three days before visiting the neurologist, a continuous headache in the left temporal lobe was developed. Figure 1. Periventricular lesions confirming the The patient was febrile at that time as well. diagnosis of multiple sclerosis (MS) in the FLAIR MRI Besides, two days before this, she had started view (A). Meningeal enhancement was seen after ciprofloxacin for treatment of a urinary gadolinium injection (B) tract infection.
    [Show full text]
  • Multiple Sclerosis Research: Diagnostics, Disease-Modifying
    S14 Journal of Neuroscience Nursing Multiple Sclerosis Research: Diagnostics, Disease-Modifying Treatments, and Emerging Therapies Kathleen Costello ABSTRACT Multiple sclerosis (MS) is a complex disease that affects the central nervous system. It is believed to be an immune mediated disease, and although the etiology remains unknown, it is believed to occur from a combination of genetic risk factors and environmental risk factors. There is no single diagnostic test for MS, and diagnostic criteria have been developed to aid the provider in making an accurate and timely diagnosis. Once a diagnosis of MS is made, treatments directed toward the inflammatory immune response should be initiated. Currently, there are 10 treatments for MS: four interferon beta products; one glatiramer acetate; one monoclonal antibodyVnatalizumab; three oral treatmentsVfingolimod, teriflunomide, and dimethyl fumarate; and one immunosuppressant agentVmitoxantrone. Each of these agents has a different administration and different risks and side effects. Numerous agents are in late stage development, and it is possible that several more agents, all with different mechanisms of action, will become available over the next several years. Keywords: alemtuzumab, daclizumab, dimethyl fumarate, disease modifying treatment, fingolimod, glatiramer acetate, interferon beta, laquinimod, MCDONALD Criteria, multiple sclerosis, natalizumab, teriflunomide ultiple sclerosis (MS) is a chronic disease of the disease from onset, known as primary progres- of the central nervous system
    [Show full text]
  • Perspectives on Multiple Sclerosis
    Review Article Perspectives on Multiple Sclerosis Robert I. Grossman and Joseph C. McGowan There is no question that MR imaging is presently the sensitivity of MR imaging, as the study does not best method for imaging multiple sclerosis (MS); yet, include state-of-the art spinal cord imaging. Com- even today, MS remains a clinical diagnosis, with the bined brain and spinal cord imaging can increase the relationship between clinical course and MR findings sensitivity to almost 100% (19). still problematic (1, 2). MR imaging appears to be the MS is a disease characterized by a variety of clinical most important test performed in the diagnostic courses. Terminology regarding clinical classification workup of MS; it has much greater impact than CSF can be confusing and even contradictory (20). Relaps- analysis and evoked potential testing (3). It is far ing-remitting MS is the most common course of the more sensitive than a clinical examination in revealing disease, initially occurring in up to 85% of patients. disease activity, as MR abnormalities are found five Exacerbations are, at the beginning, followed by re- to 10 times more often than clinical abnormalities missions, but over a period of years, additional exac- detected by standard neurologic examination (4–8). erbations result in incomplete recovery. Within 10 In this review, we briefly summarize the clinical and years, 50% (and within 25 years, 90%) of these pa- pathologic hallmarks of MS and discuss the MR find- tients enter a progressive phase, termed secondary- ings in this disease, examining the strengths and progressive (or relapsing-progressive) MS, in which weakness of conventional imaging protocols in rela- deficits are progressive without much remission in the tion to their clinical utility.
    [Show full text]
  • Demyelination: What Is It and Why Does It Happen?
    Demyelination: What Is It and Why Does It Happen? • Causes • Symptoms • Types • MS and Demyelination • Treatment and Diagnosis • Vaccines • Takeaway What is demyelination? Nerves send and receive messages from every part of your body and process them in your brain. Nerves allow you to speak, see, feel, and think. Many nerves are coated in myelin. Myelin is an insulating material. When it’s worn away or damaged, nerves can deteriorate, causing problems in the brain and throughout the body. Damage to myelin around nerves is called demyelination. Nerves Nerves are made up of neurons. Neurons are composed of a cell body, dendrites, and an axon. The axon sends messages from one neuron to the next. The axon also connects neurons to other cells, such as muscle cells. Some axons are extremely short. Others are 3 feet long. Some axons are covered in myelin. Myelin protects the axons and helps carry axon messages as quickly as possible. Myelin Myelin is made of membrane layers that cover an axon. This is similar to the idea of an electrical wire with coating to protect the metal underneath. Myelin allows a nerve signal to travel faster. In unmyelinated neurons, a signal can travel along the nerves at about 1 meter per second. In a myelinated neuron, the signal can travel 100 meters per second. Certain diseases can damage myelin. Demyelination slows down messages sent along axons and causes the axon to deteriorate. Depending upon the location of the damage, axon loss can cause problems with feeling, moving, seeing, hearing, and thinking clearly. CAUSES Causes of demyelination Inflammation is the most common cause of myelin damage.
    [Show full text]